Therapeutic effects of aripiprazole in the 5xfad alzheimer’s disease mouse model

Ye Ji Jeong, Yeonghoon Son, Hye Jin Park, Se Jong Oh, Jae Yong Choi, Young Gyu Ko, Hae June Lee

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Global aging has led to growing health concerns posed by Alzheimer’s disease (AD), the most common type of dementia. Aripiprazole is an atypical FDA-approved anti-psychotic drug with potential against AD. To investigate its therapeutic effects on AD pathology, we administered aripiprazole to 5xFAD AD model mice and examined beta-amyloid (βA)-induced AD-like phenotypes, including βA production, neuroinflammation, and cerebral glucose metabolism. Aripiprazole administration significantly decreased βA accumulation in the brains of 5xFAD AD mice. Aripiprazole significantly modified amyloid precursor protein processing, including carboxyl-terminal fragment β and βA, a disintegrin and metalloproteinase domain-containing protein 10, and betasite APP cleaving enzyme 1, as determined by Western blotting. Neuroinflammation, as evidenced by ionized calcium binding adapter molecule 1 and glial fibrillary acidic protein upregulation was dramatically inhibited, and the neuron cell layer of the hippocampal CA1 region was preserved following aripiprazole administration. In 18F-fluorodeoxyglucose positron emission tomography, after receiving aripiprazole, 5xFAD mice showed a significant increase in glucose uptake in the striatum, thalamus, and hippocampus compared to vehicle-treated AD mice. Thus, aripiprazole effectively alleviated βA lesions and prevented the decline of cerebral glucose metabolism in 5xFAD AD mice, suggesting its potential for βA metabolic modification and highlighting its therapeutic effect over AD progression.

Original languageEnglish
Article number9374
JournalInternational journal of molecular sciences
Issue number17
Publication statusPublished - 2021 Sept 1

Bibliographical note

Funding Information:
Funding: This work was supported by a grant of the Korea Institute of Radiological and Medical Sciences (No. 50531-2021) and the National Research Foundation of Korea (NRF-2020R1C1C1006659) funded by the Korean government Ministry of Science and ICT (MSIT).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


  • Alzheimer’s disease mice
  • Aripiprazole
  • Therapeutic agent
  • βA pathology

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Therapeutic effects of aripiprazole in the 5xfad alzheimer’s disease mouse model'. Together they form a unique fingerprint.

Cite this